Several inherited polymorphisms are associated with risk of venous thrombosis, including mutation at codon 506 of the factor V gene, mutation at position 20210 of the prothrombin gene, and mutations in the protein C gene. In this study, genotyping for factor V, prothrombin, and protein C mutations was performed in 50 patients and 25 control subjects by polymerase chain reaction—based analysis. The prevalence of factor V and prothrombin mutations was not significantly different from that in the general population. Nine of the patients had heterozygous protein C mutation. There was a high prevalence of the mutated protein C allele in the pulmonary emboli group (42.8%). Protein C mutation incidence was higher in the pulmonary emboli group than in the deep vein thrombosis (8.33%) and cerebral vein thrombosis (16.1%) groups. These results indicate that patients with protein C deficiency have a greater risk of thrombosis than patients with factor V or prothrombin G20210A mutation.
Bertina RM, Rosendaal FRVenous thrombosis-the interaction of genes and environment. N Engl J Med. 1998;338:1840-1841.
2.
Lane DA, Grant PJRole of hemostatic gene polymorphisms in venous and arterial thrombotic disease . Blood. 2000;95:1517-1532.
3.
Esmon CTThe protein C anticoagulant pathway. Arterioscler Thromb. 1992;12:135-145.
4.
Kisiel W., Canfield WM, Ericsson LH, et al. Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry. 1977 ;16:5824-5831.
5.
Amphlett GW, Kisiel W., Castellino FJInteraction of calcium with bovine plasma protein C. Biochemistry . 1981;20:2156-2161.
6.
Griffin JH, Evatt B., Zimmerman TS, et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981;68:1370-1373.
De Stefano V. , Finazzi G., Mannucci PMInherited thrombophilia: pathogenesis, clinical syndromes and management. Blood. 1996;87:3531-3544.
9.
Dahlbäck B., Carlsson M., Svensson PJFamilial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004-1008.
10.
Zoller B., Dahlbäck B.Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994 ;343:1536-1538.
11.
Bertina RM, Koeleman BP, Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
12.
Voorberg J. , Roelse J., Koopman R., et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994;343: 1535-1536.
13.
Greengard JS , Eichinger S., Griffin JH, et al. Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg→Gln mutation in the gene for factor V. N Engl J Med . 1994;331:1559-1562.
14.
Dawie EW, Fujikawa K., Kisiel W.The coagulation cascade: initiation, maintenance and regulation. Biochemistry. 1991; 30:10363-10370.
15.
Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
16.
Brown K., Luddington R., Williamson D., et al. Risk of venous thromboembolism associated with G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene . Br J Haematol. 1997;98:907-909.
17.
Margaglione M., Brancaccio V., Giuliani N., D'Andrea et al. Increased risk for venous thrombosis in carriers of the prothrombin G→A20210 gene variant. Ann Intern Med. 1998;129:89-93.
18.
Bank I., Tick LW, Hutten BA, Kramer, et al. Acquired and inherited thrombophilic factors and the risk for residual venous thrombosis . Pathophysiol Haemost Thromb. 2003;33:192-196.
19.
Simioni P., Sanson BJ, Prandoni P., et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost. 1999;81:198-202.
20.
Bucciarelli P., Rosendaal FR, Tripodi A., et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol. 1999;19:1026-1033.
21.
Prandoni P. , Lensing AW, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med . 2002;137:955-960.
22.
Kyrle PA, Minar E., Hirschl M., et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000 ;343:457-462.
23.
Ma AD, Hagstrom N., High KA, et al. Activated protein C resistance and factor V Leiden. Adv Pathol. 1996;9:311-328.
24.
Margaglione M. , Brancaccio V., De Lucia D., et al. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism. Chest. 2000;118: 1405-1411.
25.
Martinelli I. , Cattaneo M., Panzeri D., et al. Low prevalence of factor V: Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost . 1997;77:440-443.
26.
Vandenbroucke JP, Bertina RM, Holmes ZR, et al. Factor V Leiden and fatal pulmonary embolism. Thromb Haemost. 1998;79:511-516.
27.
Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, et al. Prevalence of the prothrombin gene variant (nt 20210) in venous thrombosis and arterial disease. Thromb Haemost. 1997;78:1430-1433.
28.
Bavikatty NR , Killeen AA, Akel N., et al. Association of the prothrombin G20210A mutation with factor V Leiden in a midwesternAmerican population. Am J Clin Pathol. 2000;114:272-275.
29.
Van der Meer FJ, Koster T., Vandenbroucke JP, et al. The Leiden Thrombophilia Study (LETS) . Thromb Haemost. 1997;78:631-635.
30.
Allaart CF, Poort SR, Rosendaal FR, et al. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet. 1993;341:134-138.
31.
Broekmans AW , Van der Linden IK, Veıtkamp JJ, et al. Prevalence of isolated protein C deficiency in patients with venous thrombotic disease and in the population [abstract]. Thromb Haemost. 1983;50:350.
32.
Leroy-Matheron C., Levent M., Pignon JM, et al. The 1691 G→A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients. Thromb Haemost. 1996;75:4-10.
33.
Rosendaal FRVenous thrombosis: a multicausal disease. Lancet. 1999;353:1167-1173.
